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Edited by Hans EklundAbstract The inhibition of hepatic glycogen-associated protein
phosphatase-1 (PP1-GL) by glycogen phosphorylase a prevents
the dephosphorylation and activation of glycogen synthase, sup-
pressing glycogen synthesis when glycogenolysis is activated.
Here, we show that a peptide (280LGPYY284) comprising the last
ﬁve amino acids of GL retains high-aﬃnity interaction with phos-
phorylase a and that the two tyrosines play crucial roles. Tyr284
deletion abolishes binding of phosphorylase a to GL and replace-
ment by phenylalanine is insuﬃcient to restore high-aﬃnity
binding. We show that a phosphorylase inhibitor blocks the inter-
action of phosphorylase a with the GL C-terminus, suggesting
that the latter interaction could be targeted to develop an anti-
diabetic drug.
 2007 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Diabetes1. Introduction
Type-2 diabetes is characterised by hyperglycaemia, the
inability of insulin to stimulate plasma glucose uptake into
peripheral tissues, defects in insulin secretion and excessive
endogenous glucose production [1]. A key objective in treating
diabetes is to lower plasma glucose levels. The liver is a major
organ regulating glucose homeostasis and when plasma
glucose levels decline postprandially, increased hepatic glyco-
genolysis and gluconeogenesis are the major routes of endo-
genous glucose production [2]. Glycogenolysis predominates
initially after fasting, while gluconeogenesis is the major route
after glycogen stores are depleted. It may be advantageous inAbbreviations: PP1, protein phosphatase 1; GL, hepatic glycogen-
targeting subunit (encoded by gene PPP1R3B); GS, glycogen synthase;
ITC, isothermal titration calorimetry
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doi:10.1016/j.febslet.2007.08.073diabetes to counteract hyperglycaemia by stimulating hepatic
GS, so that conversion of blood glucose to hepatic glycogen
is accelerated. One possible way of achieving this would be
to increase the activity of the hepatic GS phosphatase, which
activates GS.
Hepatic GS is regulated both allosterically by glucose-6-
phosphate and by phosphorylation of multiple serine residues
[3,4]. Phosphorylation is catalysed by several protein kinases
that inactivate GS, while dephosphorylation by glycogen-tar-
geted PP1 activates GS. The major form of glycogen-targeted
PP1 in the liver is PP1-GL, which is controlled allosterically by
the active ‘a’ form of glycogen phosphorylase [5,6]. When gly-
cogenolysis is stimulated, glycogen phosphorylase b is con-
verted to phosphorylase a by phosphorylation of Ser14.
Phosphorylase a binds to the GL regulatory subunit of PP1-
GL, preventing the activation of GS, without aﬀecting the inac-
tivation of phosphorylase a by PP1-GL. This allosteric regula-
tion of PP1-GL allows glycogen synthesis to be switched oﬀ
when glycogenolysis is stimulated. Phosphorylase a must be
converted back to phosphorylase b almost completely before
glycogen synthesis ensues [5]. Previous studies have demon-
strated that the C-terminal 16 residues of GL are suﬃcient
for interaction with phosphorylase a [7]. Here, we have identi-
ﬁed the key amino acids within the 16mer that are essential for
binding. We also show that CP-316819, a member of the in-
dole-2-carboxamide series of phosphorylase inhibitors [8] is
capable of modulating the interaction of the GL 16mer peptide
with phosphorylase a.2. Materials and methods
2.1. Materials
Glycogen phosphorylase a was prepared by phosphorylation of rab-
bit skeletal muscle phosphorylase b with phosphorylase kinase (both
puriﬁed by Dr. James Hastie) to a stoichiometry of 1 mol of phos-
phate/mol phosphorylase subunit [9]. Peptides were synthesised by
Dr. Graham Bloomberg, University of Bristol, UK. 5-Chloro-N-
[(1R,2S)-2-hydroxy-3-(methyloxymethylamino)-3-oxo-1-(phenylmeth-
yl)propyl]-1H-Indole-2-carboxamide (CP-316819) was synthesised by
Pﬁzer Global Research and Development [10].
2.2. Isothermal titration calorimetry
ITC measurements were performed in degassed 50 mM Tris–HCl,
pH 7.0, 1 mM DTT at 20 C using a VP-ITC instrument (MicroCal,
LLC, Northampton, MA). Unless otherwise stated, titrationsblished by Elsevier B.V. All rights reserved.
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4750 I.R. Kelsall et al. / FEBS Letters 581 (2007) 4749–4753consisted of a preliminary 5 ll injection of 0.32 mM GL peptide solu-
tion followed by 19 injections of 10 ll peptide into the reaction cell,
which contained 1.4 ml of 0.025 mM phosphorylase a monomer solu-
tion. Typically, 180–240 s equilibration time was allowed between
injections to allow heat measurements to return to baseline. The heat
of dilution in separate titrations of both peptide into buﬀer and buﬀer
into phosphorylase solutions was determined to be negligible. In order
to determine the eﬀect of CP-316819 on binding, 0.025 mM phosphor-
ylase amonomer was pre-incubated with 0.3–10 lM of drug for 45 min
at 30 C with shaking in 50 mM Tris–HCl, pH 7.0, 1 mM DTT, 0.1%
(v/v) DMSO. Titrations were then performed as before but with the
addition of 0.1% (v/v) DMSO to all solutions. Calorimetric data anal-
ysis were carried out with ORIGIN 7.0 software. Integration of the
raw heat data using a one-binding-site model yielded a diﬀerential ther-
mal binding curve, the equilibrium constant for association of phos-
phorylase a with the GL-derived peptides (Ka), the enthalpy (DH)
and entropy (DS) of binding.B
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Fig. 1. Interaction of the 16 C-terminal amino acids of GL with
phosphorylase a. (A) Schematic representation of GL showing the C-
terminal phosphorylase a binding site. The PP1, glycogen and
substrate binding domains of GL are indicated. The sequence of the
phosphorylase a binding region of GL, which is identical in humans,
mouse and rat, is shown [7]. (B) Titration of phosphorylase a by the GL
peptide 269PEWPSYLGYEKLGPYY284. The upper panel shows the
raw data for one experiment, generated by titration of 1.8 ml of
0.025 mM rabbit skeletal muscle phosphorylase a by 20 injections
(12 ll) of 0.32 mM GL 16mer. The lower panel shows the integrated
area within each peak (from the baseline shown) plotted against the
molar ratio of the GL 16mer to phosphorylase a monomer. The
smooth line represents the best ﬁt of the experimental data to a model
with one set of sites. The Kd for the binding of the GL 16mer to
phosphorylase a in this experiment was 0.20 lM.3. Results
3.1. Analysis of the interaction of GL with phosphorylase a
Initial experiments showed that [32P] labelled skeletal muscle
glycogen phosphorylase a interacted with bacterially-expressed
glutathione-S-transferase-GL [7] on membranes in the absence
or presence of 50 mM glucose or 5 mM caﬀeine (data not
shown) but not in the presence of 3 mM AMP as noted previ-
ously [6]. The binding of a peptide comprising the 16C-termi-
nal residues of GL (Fig. 1A) to phosphorylase a was
determined by ITC to be exothermic and saturating at a stoi-
chiometry (n) of 1:1 (Fig. 1B; Table 1). The dissociation con-
stant Kd (the reciprocal of Ka) is in the nanomolar range
(218 ± 111 nM for four experiments). The binding reaction is
enthalpy-driven (DH = 11.8 kcal/mol) and entropically unfa-
vourable (TDS = 2.5 kcal/mol) displaying entropy/enthalpy
compensation eﬀects typical of biomolecular interactions.
ITC with a series of truncated peptides (Table 1 upper half)
showed that the Kd was largely unaﬀected when the 16 residue
peptide was truncated to the C-terminal 13 or 11 amino acids
of GL. Although the binding aﬃnity was decreased (Kd
860 nM) when Tyr274 and Leu 275 were removed, a Kd value
of 854 nM was still observed for a peptide comprising only the
5C-terminal amino acids 280LGPYY284 (rodent numbering).
Alanine scanning analysis of the peptide comprising the nine
C-terminal amino acids (276GYEKLGPYY284) showed that
substitution of Leu280 or Pro282 by Ala weakened the binding
aﬃnity of the peptide (Kd 1.1 and 1.5 lM, respectively), while
substitution of Lys279 or Gly281 actually increased the aﬃnity
to that seen for the wild-type 16mer peptide (Table 1, lower
half). The enthalpical component of the binding energy was in-
creased, although this was counterbalanced by an unfavour-
able reduction in entropy. Replacement of Tyr283 by Ala
completely abolished binding, as did deletion of Tyr284 in
the 11mer and 13mer, indicating the critical importance of
these two C-terminal tyrosine residues in the interaction with
phosphorylase a. Substitution of Tyr283 by the structurally
similar amino acid Phe severely decreased the binding aﬃnity
of the peptide (Kd = 3.2 ± 0.8 lM). Substitution of the C-ter-
minal Tyr284 by phenylalanine was suﬃcient to completely
disrupt the interaction of the 8mer peptide with phosphorylase
a (Fig. 2B), as was substitution of both Tyr283 and Tyr284 by
Phe. Replacement of Tyr284 by Phe within the 16mer did not
abolish binding but severely decreased the Kd, which was esti-
mated at 24.5 ± 11.6 lM (Table 1). Overall the data indicate acritical role for the C-terminal Tyr284 of GL in the interaction
with phosphorylase a.
3.2. Eﬀect of the glycogen phosphorylase inhibitor CP-316819
on the interaction of GL with phosphorylase a
The development of inhibitors of phosphorylase a, such as
CP-316819 an indole-2-carboxamide [10], capable of decreas-
ing hepatic glucose output raised the question of whether
any of these compounds aﬀect the binding of GL to phosphor-
ylase a. We found that CP-316819 inhibited phosphorylase a in
the presence of 7.5 mM glucose with an IC50 of 57 nM as
found previously [8]. Calorimetric analysis of the interaction
Table 1
Thermodynamic parameters for the association of various GL-derived peptides with glycogen phosphorylase a
Peptide sequence n Kd (nM) DH (kcal/mol) TDS (kcal/mol) DG (kcal/mol)
a
PEWPSYLGYEKLGPYY 0.95 (±0.10) 218 (±111) 11.8 (±0.7) 2.5 (±0.4) 9.3 (±0.8)
PSYLGYEKLGPYY 0.80 (±0.02) 374 (±48) 13.5 (± 0.5) 4.9 (±0.5) 8.6 (±0.7)
YLGYEKLGPYY 0.80 (±0.31) 297 (±97) 13.4 (± 4.7) 4.6 (±2.9) 8.8 (±5.5)
GYEKLGPYY 0.92 (±0.01) 860 (±38) 12.3 (±0.05) 4.1 (±0.1) 8.2 (±0.1)
YEKLGPYY 0.88 (±0.03) 825 (±56) 12.2 (±0.05) 4.0 (±0.1) 8.2 (±0.1)
EKLGPYY 1.08 (±0.04) 801 (±44) 9.7 (±0.1) 1.5 (±0.05) 8.2 (±0.1)
KLGPYY 1.07 (±0.003) 655 (±71) 12.3 (±0.1) 4.0 (±0.2) 8.3 (±0.2)
LGPYY 1.00 (±0.05) 854 (±87) 11.1 (±0.2) 2.9 (±0.2) 8.2 (±0.3)
GYEKLGPAY NB NB NB NB NB
GYEKLGAYY 0.93 (±0.01) 1141 (±53) 11.8 (±0.1) 3.8 (±0.1) 8.0 (±0.1)
GYEKLAPYY 0.59 (±0.03) 305 (±97) 17.6 (±0.04) 8.8 (±0.2) 8.8 (±0.2)
GYEKAGPYY 1.03 (±0.03) 1527 (±255) 10.7 (±0.5) 2.9 (±0.6) 7.8 (±0.8)
GYEALGPYY 0.59 (±0.03) 177 (±59) 17.3 (±0.5) 8.2 (±0.7) 8.3 (±0.9)
GYAKLGPYY 1.02 (±0.03) 968 (±117) 11.5 (±0.1) 3.4 (±0.1) 8.1 (±0.1)
PSYLGYEKLGPY_ NB NB NB NB NB
YLGYEKLGPY_ NB NB NB NB NB
YEKLGPFY 0.80 (±0.004) 3202 (±759) 10.7 (±0.4) 3.3 (±0.5) 7.4 (±0.6)
YEKLGPFF NB NB NB NB NB
YEKLGPYF NB NB NB NB NB
PEWPSYLGYEKLGPYF 0.75 (±0.09) 24476 (± 11644) 11.0 (±1.7) 4.5 (±1.9) 6.5 (±2.5)
All experiments were performed in triplicate, with the exception of the PSYLGYEKLGPY_ peptide, the result of which is from a single experiment
only, and the PEWPSYLGYEKLGPYY and the PEWPSYLGYEKLGPYF peptides, the data for which is derived from four separate binding
exotherms. The errors given correspond to the standard error of the mean unless otherwise indicated. n is the stoichiometry of binding of each peptide
to phosphorylase a monomer. NB means that the experiments have been performed, but no binding was detected.
aCalculated from the equation DG = DH  TDS. The errors given are the square root of the sum of the squares of DH and TDS.
Fig. 2. Titration of phosphorylase a by the GL (277–284) peptide and the Y284F mutant peptide. Phosphorylase a was titrated with 20 injections of
(A) YEKLGPYY and (B) YEKLGPYF at 20 C. The upper traces show the raw data and the lower traces show the binding isotherms in terms of
heat per injected peptide vs. molar ratio of peptide to phosphorylase a monomer. The mutation of the extreme C-terminal tyrosine residue to
phenylalanine completely abolishes binding to phosphorylase a.
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269PEWPSYLGYEKLGPYY284 with
phosphorylase a, in the presence of increasing concentrations
of CP-316819, showed that the binding aﬃnity of the peptide
was decreased at 1 lM CP-316819 and above (Table 2).
5 lM CP-316819 decreased the overall reaction enthalpy and
modiﬁed the integrated binding isotherm to a more shallow
curve (Fig. 3B, lower panel). 10 lM CP-316819 resulted inraw data (Fig. 3C, upper panel) that was not signiﬁcantly dif-
ferent from heats of dilution and mixing determined in con-
trols, indicating that 10 lM CP-316819 was suﬃcient to
completely block the interaction of the 16mer GL peptide with
25 lM phosphorylase a. Although in vivo muscle phosphory-
lase a is a dimer, in vitro at 25 lM phosphorylase a may be
mainly tetrameric [11,12]. The ratio, CP-316819: phosphory-
Table 2
Thermodynamic parameters for the association of the PEWPSYLGYEKLGPYY peptide with 25 lM phosphorylase a monomer in the presence of
the indicated concentrations of CP-316819
CP-316819 concentration (lM) n Kd (nM) DH (kcal/mol) TDS (kcal/mol) DG (kcal/mol)
0 0.95 (±0.10) 218 (±111) 11.8 (±0.7) 2.5 (±0.4) 9.3 (±0.8)
0.3 0.59 (±0.04) 135 (±20) 10.9 (±0.4) 1.2 (±0.2) 9.7 (±0.4)
1 0.90 (±0.03) 888 (±122) 11.0 (±0.4) 2.8 (±0.5) 8.2 (±0.6)
5 1.15 (±0.17) 1917 (±423) 7.9 (±1.3) 0.2 (±1.2) 7.7 (±1.8)
10 NB NB NB NB NB
Experiments at CP-316819 concentrations 0 and 10 lM were performed in quadruplicate. All other experiments were performed in triplicate.
Fig. 3. ITC data for phosphorylase a binding to the PEWPSYLGYEKLGPYY peptide (A) in the absence of CP-316819, (B) following pre-
incubation of phosphorylase with 5 lM CP-316819, (C) following pre-incubation of phosphorylase with 10 lM CP-316819. The upper traces show
the raw heat data and the lower traces show the ﬁt of a 1:1 binding model after integration of the raw data. 10 lM CP-316819 blocks the interaction
of the peptide with 25 lM phosphorylase a monomer.
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gests that homotropic cooperative eﬀects between the subunits
of phosphorylase a allow inhibition of approximately two sub-
units in the tetramer (or one subunit in the dimer) to alloster-
ically change the conformation of the other subunits(s) to the
inhibited structure [13].4. Discussion
We show here that the site of interaction of GL with phos-
phorylase a is even smaller than the 16 C-terminal residues
of GL previously determined [7]. A peptide comprising the ﬁve
C-terminal amino acids 280LGPYY284 formed a complex with
phosphorylase a, with only slightly lower aﬃnity than the
16mer peptide. The two C-terminal tyrosines play critical roles
in binding; replacement of either by the structurally similar
amino acid Phe is insuﬃcient to retain the nanomolar aﬃnity
of the GL peptides for phosphorylase a, suggesting that the
tyrosine hydroxyls are crucial for interaction with phosphory-
lase a. The marginally increased dissociation constants when
Leu280 or Pro282 are replaced by Ala raise the possibility that
Pro282 may allow favourable presentation of the tyrosines tophosphorylase a, and Leu280 may provide hydrophobic inter-
actions. Thus, the consensus sequence for initiation of the
interaction is LXPYY, where x may be Gly, Ala or possibly
other amino acids. The crucial interaction of GL with phos-
phorylase a involves the two tyrosine residues at the C-termi-
nus, with the C-terminal Tyr284 playing the major role.
The Kd of 218 nM for the binding of phosphorylase a to the
GL 16mer determined by ITC is consistent with the earlier
analyses employing immobilised GST-GL [7,14] and glyco-
gen-bound GS phosphatase [15]. Our data indicate that each
phosphorylase a dimer binds two molecules of GL (Table 1).
Since GL binding occurs in the presence of glucose and caf-
feine, which bind to distinct sites that are homologous in mus-
cle and liver phosphorylases [16,17], GL is not binding at these
sites. The interaction sites for AMP in liver and muscle phos-
phorylase a are homologous, lying across the dimeric subunit
interface, where each AMP binds between a loop from one
subunit (containing the phosphorylated Ser14) and a helix
of the other subunit [18,19]. Since AMP prevents the binding
of GL to muscle phosphorylase a, AMP binding may either
cause a conformational change that prevents the GL interac-
tion or the binding sites for AMP and the GL C-terminus
overlap.
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glycaemic agents that may be useful in the treatment of diabe-
tes to counteract elevated hepatic glucose output. The indole-
2-carboxamide series of phosphorylase inhibitors reached
phase II clinical trials [23] and have been shown to bind to
muscle and liver phosphorylases at a novel allosteric site lo-
cated at the dimeric subunit interface [20,21]. Interestingly,
CP-316819 is able to completely block the binding of GL to
muscle phosphorylase a, raising the possibility that GL binds
at or near the indole-2-carboxamide binding site on phosphor-
ylase a. However, the interaction sites for indole-2-carboxam-
ide inhibitors and AMP on phosphorylase a are distinct, and
the GL C-terminus could not contact both binding sites. More
likely, conformational changes induced by the binding of in-
dole-2-carboxamide drugs prevent the binding of GL to phos-
phorylase a. These inhibitors can interact with the active and
inactive conformations of phosphorylase a, but are likely to
favour the inactive conformation [20].
The ﬁnding that CP-316819 blocks the binding of GL to
phosphorylase a suggests that the indole-2-carboxamide drugs
(used in the lM range) may exert their eﬀects on hepatic glu-
cose output not only by inhibition of liver phosphorylase a
but also by lowering the aﬃnity of phosphorylase a for PP1-
GL. While the inhibition of phosphorylase a is a valid strategy
for attenuating hyperglycaemia in type 2 diabetes, the drugs
developed to date inhibit both liver and muscle phosphorylases
and inhibition of the latter may be detrimental because it im-
pairs aerobic muscle function during prolonged contraction
[22]. A drug that inhibits the interaction of GL with phosphor-
ylase a and not phophorylase a itself avoids this problem. The
discovery that a small region of GL binds to phosphorylase a
indicates that it should be possible to develop a small molecule
drug capable of disrupting the interaction. A drug binding to
GL should be eﬀective at far lower concentrations in vivo than
a phosphorylase a inhibitor [23] due to the lower concentration
of GL in the liver. Disruption of the allosteric regulation of
PP1-GL by phosphorylase a may also create an energy-con-
suming glycogenolytic–glycogen synthetic cycle, which could
be advantageous. In addition, such a drug may operate in hu-
man muscle, where PP1-GL is also expressed [24].
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